| P50 | author | Keith A. Sharkey | Q38328653 |
| P2093 | author name string | Jonathan B Meddings | |
| | V Wee Yong | |
| | Carlos R Camara-Lemarroy | |
| | Luanne Metz | |
| P2860 | cites work | Coeliac disease presenting with acute disseminated encephalomyelitis | Q82611155 |
| | Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis | Q83395408 |
| | Phenotypic localization of distinct DC subsets in mouse Peyer Patch | Q83719308 |
| | A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease | Q84371124 |
| | Influence of alemtuzumab on the intestinal Paneth cells and microflora in macaques | Q84530839 |
| | Silent neurological involvement in biopsy-defined coeliac patients | Q86651937 |
| | A CD52 antibody impairs mouse-transplanted intestinal tight junctions | Q86969801 |
| | [Cellular composition of Peyer's patches and peripheral lymph nodes in experimental allergic encephalomyelitis during fingolimod therapy] | Q95616637 |
| | Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung | Q21131368 |
| | Microbial view of central nervous system autoimmunity | Q22252213 |
| | The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate | Q26771888 |
| | Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis | Q26781285 |
| | Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation | Q26995831 |
| | Dendritic cell subsets in the intestinal lamina propria: ontogeny and function | Q26997819 |
| | Intestinal barrier in inflammatory bowel disease | Q27023724 |
| | Selective accumulation of pro-inflammatory T cells in the intestine contributes to the resistance to autoimmune demyelinating disease | Q27323594 |
| | Molecular Mimicry Revisited: Gut Bacteria and Multiple Sclerosis | Q27473292 |
| | Inflammatory bowel disease: an increased risk factor for neurologic complications | Q27690759 |
| | Therapeutic potential of fecal microbiota transplantation | Q28298108 |
| | Can probiotics modulate human disease by impacting intestinal barrier function? | Q28817192 |
| | Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens | Q28818329 |
| | Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis | Q29547656 |
| | Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis | Q29619978 |
| | The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. | Q30479623 |
| | Intravital observation of adhesion of lamina propria lymphocytes to microvessels of small intestine in mice | Q31041039 |
| | Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. | Q31151767 |
| | FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. | Q33271908 |
| | Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia | Q33593133 |
| | Interaction between the gut microbiome and mucosal immune system | Q33612504 |
| | Leaky Gut As a Danger Signal for Autoimmune Diseases | Q33715465 |
| | Homeostasis of the gut barrier and potential biomarkers | Q33715804 |
| | Structure and function of tight junctions. Role in intestinal barrier. | Q33781217 |
| | Prevalence of celiac disease in multiple sclerosis | Q33840141 |
| | High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis | Q33898849 |
| | Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function | Q33899677 |
| | Neurological disorders and inflammatory bowel diseases | Q33958822 |
| | The blood-brain barrier in multiple sclerosis: microRNAs as key regulators. | Q38329179 |
| | Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease | Q38460376 |
| | Innate lymphoid cells in intestinal immunity and inflammation | Q38605374 |
| | The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. | Q38613269 |
| | Cell death at the intestinal epithelial front line. | Q38616012 |
| | Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects | Q38643163 |
| | Multiple sclerosis and infections | Q38649264 |
| | Neurological disorders and celiac disease | Q38653470 |
| | The role of diet in multiple sclerosis: A review. | Q38740469 |
| | Type 1 Interferon in the Human Intestine-A Co-ordinator of the Immune Response to the Microbiota. | Q38744710 |
| | CD44 deletion leading to attenuation of experimental autoimmune encephalomyelitis results from alterations in gut microbiome in mice. | Q38764574 |
| | Developmental expression of STATs, nuclear factor-κB and inflammatory genes in the jejunum of piglets during weaning | Q38772188 |
| | Influence of the Gut Microbiome on Autoimmunity in the Central Nervous System | Q38772593 |
| | Using peptides to increase transport across the intestinal barrier | Q38828115 |
| | Dietary Interventions and Multiple Sclerosis | Q38895161 |
| | Celiac Disease: Role of the Epithelial Barrier | Q38919389 |
| | The intestinal epithelial barrier: a therapeutic target? | Q39009998 |
| | Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis | Q39017663 |
| | Barrier function in the peripheral and central nervous system-a review. | Q39037187 |
| | Interferon-γ-induced intestinal epithelial barrier dysfunction by NF-κB/HIF-1α pathway | Q39062844 |
| | The mucosal barrier at a glance. | Q39071909 |
| | Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases | Q39103865 |
| | Improvement of a 'Leaky' Intestinal Barrier | Q39113717 |
| | Contributions of intestinal epithelial barriers to health and disease | Q39200576 |
| | The role of the gut microbiota in sepsis | Q39238517 |
| | Vitamin D signaling in intestinal innate immunity and homeostasis | Q39244762 |
| | Type I Interferons Control Proliferation and Function of the Intestinal Epithelium | Q39253946 |
| | Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. | Q39268623 |
| | Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease | Q39339639 |
| | Brain Autoimmunity and Intestinal Microbiota: 100 Trillion Game Changers | Q39364276 |
| | Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier. | Q39388017 |
| | Signaling and epigenetic mechanisms of intestinal stem cells and progenitors: insight into crypt homeostasis, plasticity, and niches | Q39394470 |
| | Small-bowel abnormalities in multiple sclerosis | Q39413550 |
| | Layered defense: how mucus and tight junctions seal the intestinal barrier | Q39434367 |
| | The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. | Q39613921 |
| | Gut microbiota in early pediatric multiple sclerosis: a case-control study | Q39768825 |
| | Reduced Mass and Diversity of the Colonic Microbiome in Patients with Multiple Sclerosis and Their Improvement with Ketogenic Diet | Q40137334 |
| | Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. | Q55052541 |
| | Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response | Q59302315 |
| | Multiple sclerosis and celiac disease: is there an increased risk? | Q60050559 |
| | Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease | Q62476200 |
| | Multiple sclerosis and malabsorption | Q67070212 |
| | Endotoxin stimulates lymphocyte-endothelial interactions in rat intestinal Peyer's patches and villus mucosa | Q71435832 |
| | Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease | Q71577663 |
| | Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo | Q71616345 |
| | Focal white-matter lesions in brain of patients with inflammatory bowel disease | Q72135622 |
| | FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing | Q77807444 |
| | The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells | Q80844197 |
| | Cerebral White Matter Lesions in Patients with Crohn's Disease | Q82526705 |
| | The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells | Q34081672 |
| | Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells | Q34128679 |
| | Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study | Q34168414 |
| | Control of TH17 cells occurs in the small intestine. | Q34201256 |
| | Inflammatory bowel disease: an impaired barrier disease | Q34312402 |
| | Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice | Q34360200 |
| | αv Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice | Q34360208 |
| | Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction | Q34409724 |
| | Host microbiota constantly control maturation and function of microglia in the CNS. | Q34478756 |
| | The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study | Q34581861 |
| | Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment | Q34596752 |
| | A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge | Q34640687 |
| | Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study | Q34645550 |
| | Human Intestinal Barrier Function in Health and Disease | Q34679342 |
| | Epithelial crosstalk at the microbiota-mucosal interface. | Q34714672 |
| | Antimicrobial resistance characteristics and fitness of Gram-negative fecal bacteria from volunteers treated with minocycline or amoxicillin | Q34722535 |
| | Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability | Q34737619 |
| | Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease | Q35022730 |
| | The light and dark sides of intestinal intraepithelial lymphocytes | Q35119562 |
| | Lymphocyte depletion after alemtuzumab induction disrupts intestinal fungal microbiota in cynomolgus monkeys | Q35227850 |
| | The gut microbiota influences blood-brain barrier permeability in mice | Q35413892 |
| | Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa | Q35498107 |
| | Gut microbiota in multiple sclerosis: possible influence of immunomodulators | Q35578319 |
| | Peyer's patch innate lymphoid cells regulate commensal bacteria expansion | Q35582872 |
| | Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. | Q35655989 |
| | Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue: relation of L-selectin and integrin alpha 4 beta 7 to naive and memory phenotypes | Q35765315 |
| | Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters | Q35773313 |
| | Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study | Q35780832 |
| | Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients | Q35811221 |
| | Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. | Q35816184 |
| | Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces | Q35837807 |
| | Apoptotic epithelial cells control the abundance of Treg cells at barrier surfaces | Q35917215 |
| | The promise of minocycline in neurology. | Q35958974 |
| | Gut microbiota composition and relapse risk in pediatric MS: A pilot study | Q35965204 |
| | Communicating systems in the body: how microbiota and microglia cooperate. | Q36071876 |
| | Association of Bactericidal Dysfunction of Paneth Cells in Streptozocin-Induced Diabetic Mice with Insulin Deficiency | Q36116340 |
| | Role of intestinal microbiota and metabolites on gut homeostasis and human diseases | Q36243299 |
| | Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. | Q36259898 |
| | The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models | Q36289990 |
| | Dimethyl fumarate reduces the risk of mycotoxins via improving intestinal barrier and microbiota | Q36390677 |
| | Reinforced Epithelial Barrier Integrity via Matriptase Induction with Sphingosine-1-Phosphate Did Not Result in Disturbances in Physiological Redox Status | Q36448467 |
| | A case of multiple sclerosis and celiac disease. | Q36567317 |
| | A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica | Q36635131 |
| | Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. | Q36669122 |
| | Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus model | Q36807186 |
| | TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway. | Q36885702 |
| | Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3. | Q36925537 |
| | Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor | Q36984429 |
| | Mechanisms of Intestinal Barrier Dysfunction in Sepsis | Q37011812 |
| | Role of toll-like receptors in multiple sclerosis | Q37021687 |
| | Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls | Q37040077 |
| | Alterations of the human gut microbiome in multiple sclerosis. | Q37060934 |
| | Dimethyl Fumarate Reduces Inflammatory Responses in Experimental Colitis | Q37098420 |
| | Physiology of Intestinal Absorption and Secretion | Q37115961 |
| | Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis | Q37123854 |
| | Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease | Q37188711 |
| | Intestinal barrier analysis by assessment of mucins, tight junctions, and α-defensins in healthy C57BL/6J and BALB/cJ mice | Q37194625 |
| | Induction of gut regulatory CD39+ T cells by teriflunomide protects against EAE. | Q37337770 |
| | The response of intestinal stem cells and epithelium after alemtuzumab administration | Q37728218 |
| | Exploring the immunomodulatory potential of microbial-associated molecular patterns derived from the enteric bacterial microbiota. | Q38121384 |
| | Lecithin as a therapeutic agent in ulcerative colitis. | Q38163748 |
| | Neurologic manifestations of inflammatory bowel diseases | Q38173511 |
| | Inflammatory bowel disease and demyelination: more than just a coincidence? | Q38184633 |
| | Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis | Q38262622 |
| | Role of the blood-brain barrier in multiple sclerosis | Q38272288 |
| | Intestinal barrier homeostasis in inflammatory bowel disease. | Q38293757 |
| | Anti-TCR antibody treatment activates a novel population of nonintestinal CD8 alpha alpha+ TCR alpha beta+ regulatory T cells and prevents experimental autoimmune encephalomyelitis | Q40137961 |
| | Isolation and Flow Cytometry Analysis of Innate Lymphoid Cells from the Intestinal Lamina Propria | Q40381607 |
| | 1,25-Dihydroxyvitamin D Protects Intestinal Epithelial Barrier by Regulating the Myosin Light Chain Kinase Signaling Pathway | Q40627574 |
| | Pancolitis a novel early complication of Alemtuzumab for MS treatment | Q40654680 |
| | FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homin | Q41042455 |
| | Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. | Q41071305 |
| | Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance | Q41137046 |
| | Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction | Q41673047 |
| | A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome | Q41836874 |
| | Sphingosine-1-Phosphate Regulates the Expression of Adherens Junction Protein E-Cadherin and Enhances Intestinal Epithelial Cell Barrier Function | Q41854266 |
| | Celiac disease with cerebral and peripheral nerve involvement mimicking multiple sclerosis. | Q42056074 |
| | Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts | Q42091545 |
| | Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. | Q42221329 |
| | Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice | Q42263596 |
| | The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis | Q42361707 |
| | CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. | Q42944577 |
| | Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. | Q43067512 |
| | Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes | Q43240144 |
| | Acute CNS white matter lesions in patients with inflammatory bowel disease | Q44070852 |
| | Effects of Bifidobacterium animalis administered during lactation on allergic and autoimmune responses in rodents | Q44165493 |
| | Larazotide acetate promotes tight junction assembly in epithelial cells | Q44979465 |
| | Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro | Q45006682 |
| | Antimicrobial susceptibility of bifidobacteria | Q45170021 |
| | Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis | Q45242443 |
| | Treatment with the sphingosine-1-phosphate analogue FTY 720 reduces loss of plasma volume during experimental sepsis in the rat. | Q45740885 |
| | Low sensitivity to glucocorticoid inhibition of in vitro Th17-related cytokine production in multiple sclerosis patients is related to elevated plasma lipopolysaccharide levels | Q45742339 |
| | Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. | Q45983167 |
| | Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases | Q46088974 |
| | The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome". | Q46181413 |
| | Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress | Q46436568 |
| | Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model | Q46480272 |
| | Effect of FTY720 in rat small bowel transplantation: expression of mucosal addressin cell adhesion molecule-1. | Q46874633 |
| | Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis | Q47577398 |
| | Blockade of both L-selectin and alpha4 integrins abrogates naive CD4 cell trafficking and responses in gut-associated lymphoid organs | Q47697901 |
| | Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. | Q47928580 |
| | The Effects of Probiotic Supplementation on Gene Expression Related to Inflammation, Insulin, and Lipids in Patients With Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial | Q47968211 |
| | Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study | Q48006929 |
| | Short-chain fatty acids augment rat duodenal mucosal barrier function. | Q48240935 |
| | Phosphoinositide 3-kinase γ affects LPS-induced disturbance of blood-brain barrier via lipid kinase-independent control of cAMP in microglial cells | Q48654975 |
| | A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation | Q48669047 |
| | Brain involvement in patients with inflammatory bowel disease: a voxel-based morphometry and diffusion tensor imaging study | Q48672090 |
| | Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. | Q48819558 |
| | High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques | Q48844459 |
| | Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier | Q49990746 |
| | Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice | Q50203353 |
| | The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. | Q50525979 |
| | Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. | Q50610530 |
| | Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. | Q52759565 |
| | Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. | Q53097289 |
| | Transverse Myelitis as Manifestation of Celiac Disease in a Toddler. | Q53530921 |
| | SEW2871 protects from experimental colitis through reduced epithelial cell apoptosis and improved barrier function in interleukin-10 gene-deficient mice. | Q53644116 |
| | Impact of antimouse CD52 monoclonal antibody on graft's γδ intraepithelial lymphocytes after orthotopic small bowel transplantation in mice. | Q54267992 |
| | Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. | Q54412643 |
| | Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma. | Q54461003 |
| P433 | issue | 7 | |
| P304 | page(s) | 1900-1916 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics | |
| P478 | volume | 141 | |